C-Met targeted fluorescence molecular endoscopy in Barrett's esophagus patients and identification of outcome parameters for phase-I studies
| Autor: | Max J. H. Witjes, Steven J de Jongh, Gooitzen M. van Dam, Gursah Kats-Ugurlu, F. J. Voskuil, Iris Schmidt, Gert Jan Meersma, Dominic J. Robinson, Wouter B. Nagengast, Arend Karrenbeld, Jessie Westerhof |
|---|---|
| Přispěvatelé: | Otorhinolaryngology and Head and Neck Surgery, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Microbes in Health and Disease (MHD), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Esophageal Neoplasms IMAGING AGENTS Biopsy Medicine (miscellaneous) EMI-137 targeting c-Met 03 medical and health sciences Barrett Esophagus Barrett's esophagus 0302 clinical medicine In vivo ADENOMAS medicine Fluorescence microscope Humans Prospective Studies Esophagus Pharmacology Toxicology and Pharmaceutics (miscellaneous) Aged business.industry standardized fluorescence molecular endoscopy methodology Middle Aged Proto-Oncogene Proteins c-met medicine.disease CANCER Structured roadmap 030104 developmental biology medicine.anatomical_structure Immunohistochemistry Neoplastic cell 030211 gastroenterology & hepatology Histopathology Female Nuclear medicine business Ex vivo Research Paper |
| Zdroj: | Theranostics, 10(12), 5357-5367. Ivyspring International Publisher Theranostics, 10(12), 5357-5367. IVYSPRING INT PUBL Theranostics |
| ISSN: | 1838-7640 |
| Popis: | Fluorescence molecular endoscopy (FME) is an emerging technique in the field of gastroenterology that holds potential to improve diagnosis and guide therapy, by serving as a 'red-flag' endoscopic imaging technique. Here, we investigated the safety, feasibility and optimal method of administration of EMI-137, targeting c-Met, during FME in Barrett's Esophagus (BE) and report several outcome parameters for early phase FME studies. Methods: FME was performed in 15 Barrett's neoplasia patients. EMI-137 was administered to three cohorts of five patients: 0.13 mg/kg intravenously (IV); 0.09 mg/kg IV or topically at a dose of 200 μg/cm BE (n=1) or 100 μg/cm BE (n=4). Fluorescence was visualized in vivo, quantified in vivo using multi-diameter single-fiber reflectance, single-fiber fluorescence (MDSFR/SFF) spectroscopy and correlated to histopathology and immunohistochemistry. EMI-137 localization was assessed using fluorescence microscopy. Results: FME using different IV and topical doses of EMI-137 appeared to be safe and correctly identified 16/18 lesions, although modest target-to-background ratios were observed (median range of 1.12-1.50). C-Met overexpression varied between lesions, while physiological expression in the stomach-type epithelium was observed. Microscopically, EMI-137 accumulated around the neoplastic cell membranes. We identified several outcome parameters important for the validation of EMI-137 for FME: 1) the optimal administration route; 2) optimal dose and safety; 3) in vivo FME contrast; 4) quantification of intrinsic fluorescence; 5) ex vivo correlation of fluorescence, histopathology and target expression; and 6) microscopic tracer distribution. Conclusions: C-Met targeted FME using EMI-137 may not be the ideal combination to improve BE surveillance endoscopies, however the identified outcome parameters may serve as a valuable guidance for designing and performing future early phase clinical FME studies, independent of which fluorescent tracer is investigated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|